Drug treatment of Parkinson’s disease: Time for phase II
- 1 May 2000
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 59 (9) , 1023-1031
- https://doi.org/10.1016/s0006-2952(99)00340-8
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Prospects for new restorative and neuroprotective treatments in Parkinson's diseaseNature, 1999
- Parkinson's disease: a major hypokinetic basal ganglia disorderJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1999
- Understanding cell death in parkinson's diseaseAnnals of Neurology, 1998
- Neuroprotective and neurorestorative properties of GDNFAnnals of Neurology, 1998
- Dopamine agonists and neuroprotection in parkinson's diseaseAnnals of Neurology, 1998
- LevodopaNeurology, 1998
- Parkinson's disease: prospects for improved drug therapyTrends in Pharmacological Sciences, 1997
- Oxidative stress and antioxidant therapy in Parkinson's diseaseProgress in Neurobiology, 1996
- The oxidant stress hypothesis in Parkinson's disease: Evidence supporting itAnnals of Neurology, 1992
- DATATOP: A Multicenter Controlled Clinical Trial in Early Parkinson's DiseaseArchives of Neurology, 1989